Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 7CNS 6Genitourinary 3NET 2Head & Neck 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Standard of Care 10Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Capecitabine 7Surveys and Questionnaires 6Gemcitabine 6Cyclophosphamide 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Radiotherapy 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gallium Ga 68 dotatate × Tumor-Agnostic × 90 days × Clear all
NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡